Compare stocks

Evaluate stocks side by side, to find the best fit for your investment goals.
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.
View stock
VS
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
View stock

Stock highlights

Stock comparison highlights
Stock name
Protalix BioTherapeuticsJohnson & Johnson
Last price
$2.75$252.14
Currency
USD
USD
$224M$599B
11.7628.82
$0.24$8.63
0.020.21
0$5.28
02.16%
Sector
HealthHealth
Employees
226138,200
Ticker
$PLX$JNJ
Primary listing
AMEXNYSE

Performance

CumulativeRolling yearsLump sum investment

Invest in $PLX or $JNJ on Lightyear

Save on broker fees and invest in 6000+ stocks and funds. When you invest, your capital is at risk.